Stock Analysis tagged as

Sector - Healthcare and Social Assistance

  • Showing 101-194 of 194 items
  • <<
  • 1
  • 2
  1. 4 ETFs On Fire Right Now

  2. The War Against Alzheimer's Requires Thinking Small

  3. How Intuitive Surgical Justifies Its Lofty Valuation

  4. 2011's Biggest Mergers and Acquisitions

  5. Neogen Is Almost Cheap

  6. 2011 In Review - Pharmaceuticals

  7. 2011 - Another Sick Year For Larger Med-Tech

  8. 2011 In Review - The Best-Performing ETFs

  9. Hill-Rom: Litigation Equals Opportunity For Investors

  10. Sanofi's Investment Prospects

  11. SonoSite Finds Its Deal

  12. Will Qiagen's Restructuring Address The Real Problems?

  13. Renewed Realism May Make Life Tech A Buy

  14. If Pipelines Matter, Novartis Should Be Looking Healthy

  15. Medtronic May Be A Heavyweight, But It Can Still Hit Hard

  16. Covidien Delivers Once Again

  17. Meridian Biosciences – Stealth Income Play

  18. Is Hologic A Coiled Spring?

  19. If CareFusion Can Execute, This Is A Major Bargain

  20. Pretty Up Your Portfolio

  21. CVS Shows Its Resilience In Any Economy

  22. Biogen Idec Has Built A Valuable Franchise

  23. No Rattle At HUM

  24. Merck's Penance Has Gone On Long Enough

  25. Zimmer Looking To Escape Its Value Trap

  26. VCA Antech Cut Down To Value

  27. Stryker Scraping By

  28. Abbott Labs Joins The Separation Movement

  29. High Yielding Equities

  30. 3 Reasons To Own Lincare Holdings

  31. PPD Goes Private

  32. The 3 Highest Yielding Pharma Stocks

  33. MELA Gets A Surprising "Yes"

  34. Endo And Forest – Dumpster-Diving In Pharma

  35. R&D The Future For Life Sciences Equipment Firms

  36. When Times Are Tough, Should Investors Go Swiss?

  37. Bio-Reference Labs Posting Impressive Internal Growth

  38. Medtronic's Healthy Growth Outlook

  39. Are Buybacks A Bad Sign?

  40. Seattle Genetics – And Now The Hard Bit

  41. Betting On Healthcare's Growth Engine

  42. Dendreon's Bull Story In Intensive Care

  43. CVS Still Needs to Prove Itself

  44. BD Healthy, But No Great Bargain

  45. The Perpetual Boston Scientific Turnaround Story

  46. Illumina Gets Capped And Cut

  47. Teva And Mylan Show Some Value Remains In Generics

  48. Covidien's Image Starting To Change

  49. Top Dividend Stocks Owned By The Pros

  50. Bard Not So Bulletproof

  51. Top Healthcare Dividend Stocks

  52. Stryker's Diversification Paying Off

  53. Should Investors Circle Back To Cubist?

  54. Huge Dividends You Can Bank On

  55. Three Safe Sectors For The Summer

  56. Should Biotech Investors Go Where Institutions Won't?

  57. Affymetrix's Downward Spiral Continues

  58. The Best IPOs From The First Half

  59. Immucor Passes Its Last Test

  60. Top Drug Stocks

  61. Investing For Growth And Value

  62. Drugstores Are A Healthy Bet

  63. Pleasure And Pain For Pfizer

  64. Johnson & Johnson Surrenders In Stents

  65. Will A Shake Up Cure AngioDynamics' Malaise?

  66. Lipitor: Pfizer's Loss Is Watson's Gain

  67. Should Investors Worry If Gen-Probe Doesn't Sell Out?

  68. 3 Reasons To Own Moog Inc.

  69. A Dull ASCO And The Usual Sell-Off

  70. Arena's New Data Doesn't Change Obesity Pill Outlook

  71. Medtronic Still Muddling Through

  72. Will Nestle Succeed Where Others Have Failed?

  73. Mergers In Orthopedics Could Heat Up Stocks

  74. Teva And Cephalon Solve Each Other's Problems

  75. 7 Dividend Stocks With Big Payouts

  76. Hologic Holding The Line

  77. Novo Nordisk Still One Of The Best Around

  78. Illumina Lights Up Again

  79. JNJ And Synthes: A Good Deal With Some Questions

  80. Teva's Rocky Road

  81. Despite The Noise, Abbott Still A Value

  82. Can St. Jude Live Up To Newfound Expectations?

  83. J&J Beats Analyst Expections, But Not Its Rivals

  84. Does Stryker Need Further Reconstruction?

  85. Amarin's Magic Pill

  86. Approval In Hand, Does Xenoport Have The Legs To Run?

  87. GNC's Solid IPO

  88. Catalyst Value Loves Medical Action Industries

  89. Valeant Offers A Princely Sum For Cephalon

  90. Consolidation And Healthcare REITs

  91. Danaher Hopes To Revive Beckman Coulter

  92. Healthcare IT Stocks Hitting Highs

  93. Novartis Building Itself Into A One-Stop Shop

  94. MannKind And The FDA - Here We Go Again

  • Showing 101-194 of 194 items
  • <<
  • 1
  • 2
Trading Center